Aliskiren is an orally active, nonpeptide, potent direct renin inhibitor that decreases plasma renin activity (PRA) and inhibits the conversion of angiotensinogen to angiotensin I. Unlike ACE ...
Three large randomized trials tested a simple idea: if one blood-pressure drug that blocks the renin-angiotensin system protects diabetic kidneys, two such drugs should protect them better. Each trial ...
a Multivariate model adjusting for cancer therapy including antimetabolites, Vascular endothelial growth factors inhibitors, taxanes, tyrosine kinase inhibitors, monoclonal antibodies, vinca alkaloids ...
Please provide your email address to receive an email when new articles are posted on . After a hyperkalemia event, mineralocorticoid receptor antagonists were discontinued in up to 46% of patients.
Please provide your email address to receive an email when new articles are posted on . Diuretics in combination with renin-angiotensin system inhibitors may slow chronic kidney disease on top of ...
Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation The following represents ...
There was no difference in major post-operative complications in patients who continued vs. stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery, according to late-breaking ...
In patients with mild or moderate chronic kidney disease, renin–angiotensin system inhibitors have improved outcomes, but less evidence supports their use in advanced CKD. New research findings are ...
Studies in animals have shown that ACE2 is used by coronaviruses as a functional receptor. ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results